Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.
Fiche publication
Date publication
octobre 2019
Journal
Clinical lung cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier, Dr MENNECIER Bertrand
Tous les auteurs :
Bennouna J, Girard N, Audigier-Valette C, le Thuaut A, Gervais R, Masson P, Marcq M, Molinier O, Cortot A, Debieuvre D, Cadranel J, Lena H, Moro-Sibilot D, Chouaid C, Mennecier B, Urban T, Sagan C, Perrier L, Barlesi F, Denis MG
Lien Pubmed
Résumé
Osimertinib, a third-generation tyrosine kinase inhibitor, is a new therapeutic option in epidermal growth factor receptor (EGFR)-mutated non-pretreated advanced non-small-cell lung cancer (NSCLC). The tumor escape mechanisms after first-line treatment with osimertinib are partially known; most of the data being obtained by analysis of circulating tumor DNA (ctDNA) from the FLAURA phase III trial.
Mots clés
EGFR mutation, Lung cancer, Resistance, Tissue biopsy, ctDNA
Référence
Clin Lung Cancer. 2019 Oct 1;: